These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 19200175

  • 1. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
    Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D, EPIC (CCR100136) study team.
    HIV Med; 2009 Feb; 10(2):116-24. PubMed ID: 19200175
    [Abstract] [Full Text] [Related]

  • 2. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
    Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, Steel H, Kleim JP, Bonny T, Millard J, ASCENT study team.
    Antivir Ther; 2008 Feb; 13(2):297-306. PubMed ID: 18505181
    [Abstract] [Full Text] [Related]

  • 3. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW, Becker S, King MS, da Silva B, Klein C, Tokimoto D, Foit C, Calhoun D, Bernstein B, Hanna GJ.
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [Abstract] [Full Text] [Related]

  • 6. The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.
    Adkison KK, Shachoy-Clark A, Fang L, Lou Y, Otto VR, Berrey MM, Piscitelli SC.
    Br J Clin Pharmacol; 2006 Sep; 62(3):336-44. PubMed ID: 16934050
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.
    AIDS; 2008 Jan 30; 22(3):385-93. PubMed ID: 18195565
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
    Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD, MaxCmin2 Trial Group.
    Antivir Ther; 2005 Jan 30; 10(6):735-43. PubMed ID: 16218173
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.
    Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, Wheeler DA, Ruane P, Mildvan D, Yangco BG, Bertz R, Bernstein B, King MS, Sun E.
    J Infect Dis; 2004 Jan 15; 189(2):265-72. PubMed ID: 14722892
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.
    J Clin Virol; 2007 Feb 15; 38(2):131-8. PubMed ID: 17208042
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
    Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, Raffi F, Cohen-Codar I, Delfraissy JF, Rouzioux C.
    J Antimicrob Chemother; 2008 Jun 15; 61(6):1344-7. PubMed ID: 18343806
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug 15; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 19. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
    Podzamczer D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, Letendre SL, Eron JJ, Brun SC, Bernstein B.
    HIV Clin Trials; 2007 Aug 15; 8(4):193-204. PubMed ID: 17720659
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.